Locum International Group


Innovative Development - Pharma Today January - December 2013 / Q1 2014

Global Technology
Locum International Research Ltd. is operates in The Strand, Cape Town and Tel Aviv, Locum International LLC in Florida USA and Locum International Group Switzerland. The Group is among the top pharmaceutical generic and pharmaceutical drug development company in the world. The company researches and develops generic formulations, manufacturing processes, scale-up and validation commercial sized procedures and markets generic and innovative controlled release and sterile pharmaceuticals as well as active pharmaceutical ingredients know-how and technology, such as the neurobiological innovative drugs (F-CRAB's, CMZ CR) worldwide in over a 175+ countries. LIG provides and presents leading FDA and EU approved SOPs, PAIs, analytical methods, ANDAs, REMS,(*) dossiers, seminars, workshops and conferences worldwide, covering both pharmaceutical and neurobiology (F-CRAB's).

Neurobiological Development - F-CRAB's / CMZ CR
LI computational neuroscientists and neurobiologists in the neurobiology development and experimental unit are currently developing advanced default protein folding mechanisms and routes for the F-CRAB RRMS drugs (relapsing remitting multiple sclerosis family of drugs), which include the development of the second generation Glatiramer Acetate Copoxane2 (COP2), with special reference to the molecular weight spectrum (Av.25+nK daltons spread and limits/10+nK->25+nK) of the truncated four amino-acid glatiramer acetate complex, which has a significant batch-2-batch (B2B-SV+RSD) synthesis variation, requiring advanced cGMP and QA/QC controls, that differ significantly from the normal drug synthesis pathways, especially in intermediate QA testing of the protected intermediates. Impeccable cleaning validation, stringent controls of starting, intermediate raw materials and solvents, resulting in significantly tighter batch to batch variations and B2B RSD's and impurity profiles, using special HPLC column and gel-filtration analytical methodology techniques.

Innovative Research
- Distribution venues
Workshops, lectures and seminars on the F-CRAB RRMS drugs, their development, synthesis, formulation, proposed default 'protein' folding, HPLC / gel filtration analysis/A.M validation and associated e-CTD/CTD specification / parameters are available as per advertised timetable in both EU and the US journal series (Contact LIG). The International Journal of Drug Development (IJDD Vol. 10/11) and the International Journal of Drug R&D (IJDR&D Vol. 11/12) are the main current print venues in the International Journal Series for publishing the ongoing F-CRAB RRMS drug innovation, experimental research and product development. Other venues include International Journal of Drug cGMP (IJGMP) and International Journal of Drug Validation (IJDV) and International Journal of Drug Master Formula and Processes (IJDM&P).

Market Highlights

Over 85% of Locum's technology sales are in Asia/China/Japan (39), North America (31) and Europe (30). For additional information contact LIGroup (www.LocumUSA.com) or IAGIM (www.iagim.org)

Pharma Today, International Journal of Generic Drugs, Times of India, Mail
and Guardian Washington Post and Times.
LIG international tel/voice messaging system US +1-561-865-6147

| F-CRAB's RRMS | Innovative Development | Locum's Long Arm |

Dictionary of Cancer Terms
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z